Lv5
1030 积分 2023-04-19 加入
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
1个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
1个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
1个月前
已完结
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group
3个月前
已完结
Adrenal Insufficiency in Adults
4个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
4个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
4个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
5个月前
已完结
Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)
5个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
6个月前
已完结
皖公网安备34019202002308
